Anle138b-F105, identified by the CAS number 2941386-44-1, is a small organic compound that has garnered interest in the field of medicinal chemistry, particularly for its potential neuroprotective properties. It is a derivative of Anle138b, which is known for its ability to inhibit the aggregation of amyloid-beta peptides, a hallmark of Alzheimer's disease. The compound is characterized by its specific molecular structure, which includes functional groups that contribute to its biological activity. Anle138b-F105 is typically studied for its effects on cellular models of neurodegeneration, where it may exhibit antioxidant properties and modulate cellular pathways involved in stress responses. Its solubility, stability, and bioavailability are critical factors that influence its efficacy in therapeutic applications. Ongoing research aims to elucidate its mechanism of action and potential as a treatment for neurodegenerative disorders, making it a compound of significant interest in pharmaceutical development.

Anle138b-F105

2941386-44-1: Anle138b-F105, identified by the CAS number 2941386-44-1, is a small organic compound that has garnered interest in the field of medicinal chemistry, particularly for its potential neuroprotective properties. It is a derivative of Anle138b, which is known for its ability to inhibit the aggregation of amyloid-beta peptides, a hallmark of Alzheimer's disease. The compound is characterized by its specific molecular structure, which includes functional groups that contribute to its biological activity. Anle138b-F105 is typically studied for its effects on cellular models of neurodegeneration, where it may exhibit antioxidant properties and modulate cellular pathways involved in stress responses. Its solubility, stability, and bioavailability are critical factors that influence its efficacy in therapeutic applications. Ongoing research aims to elucidate its mechanism of action and potential as a treatment for neurodegenerative disorders, making it a compound of significant interest in pharmaceutical development.

<p>Anle138b-F105 is an autophagy-targeting chimera (AUTOTAC) with a DC50 value of 3 nM. It targets tauP301L for lysosomal degradation.</p>

CAS 2941386-44-1

Anle138b-F105

Anle138b-F105

Ref: TM-T88731